Posts by: Alice Melão

News

CrownBio has established an agreement with the University of Utah to acquire and commercialize the university’s unique collection of patient-derived mouse models of breast cancer. The models were developed ... Read more

September 7, 2018

Health Canada Approves Perjeta Combo Therapy for Early Breast Cancer After Surgery

News

Health Canada has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy to prevent the recurrence of early breast cancer after surgery. The combination is ... Read more

August 29, 2018August 29, 2018

A Primary Breast Cancer Tumor Can Inhibit Cancer Cells from Forming Secondary Tumors, Mice Study Shows

News

Some types of breast cancers can prevent the development of secondary tumors elsewhere in the body, a process known as metastasis, through an immune-mediated inflammatory mechanism, an international research ... Read more

August 10, 2018

FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

News

The U.S. Food and Drug Administration (FDA) approved the non-radioactive tracer Magtrace for the pre-surgical detection of lymph nodes affected by breast cancer. Used in combination with Sentimag Magnetic ... Read more

July 25, 2018

Two New Indications of Kisqali Approved in US for Advanced Breast Cancers

News

Kisqali (ribociclib) now can be used in combination with an aromatase inhibitor as first-line therapy for all women with HR-positive, HER2-negative advanced or metastatic breast cancer in the United ... Read more

June 27, 2018June 27, 2018

Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal

News

Adding investigational therapy chidamide to Aromasin (exemestane) significantly delayed disease progression or death in patients with advanced breast cancer, results from a Phase 3 trial show. This means that the pivotal trial (NCT02482753) ... Read more

June 18, 2018

Zejula-Keytruda Shows Promising Response Rates for Triple-negative Breast Cancer in Phase 1/2 Trial

News

A combination of Keytruda (pembrolizumab) and Zejula (niraparib) has shown promising and durable response rates in triple-negative breast cancer patients, regardless of their BRCA mutational status, Phase 1/2 trial data show. The ... Read more

May 11, 2018

OncoSec, Merck Partner to Test Immunotherapy Combo in Phase 2 Trial for Triple-negative Breast Cancer

News

OncoSec Medical and Merck have joined efforts to conduct a Phase 2 trial evaluating the safety and effectiveness of ImmunoPulse IL-12 in combination with Keytruda (pembrolizumab) for the treatment ... Read more

May 2, 2018

ADC Therapeutics Halts ADCT-502 Development, Phase 1 Trial for HER2-positive Cancers

News

ADC Therapeutics has halted the development of ADCT-502, an investigational treatment candidate for HER2-positive solid cancers, and terminated its Phase 1 trial after it failed to show sufficient patient ... Read more

April 9, 2018

Breast Cancer Patients with Very Small Tumors May Skip Lymph Node Biopsies, Study Suggests

News

Patients with very small, invasive breast tumors — called microinvasive breast carcinomas — may not benefit from lymph node biopsies, researchers from Allina Health suggest. The study, “Clinicopathologic analysis of a ... Read more

Posts by: Alice Melão

Alice Melão

CrownBio Acquires Patient-derived Breast Cancer Mouse Models from University of Utah

Health Canada Approves Perjeta Combo Therapy for Early Breast Cancer After Surgery

A Primary Breast Cancer Tumor Can Inhibit Cancer Cells from Forming Secondary Tumors, Mice Study Shows

FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

Two New Indications of Kisqali Approved in US for Advanced Breast Cancers

Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal

Zejula-Keytruda Shows Promising Response Rates for Triple-negative Breast Cancer in Phase 1/2 Trial

OncoSec, Merck Partner to Test Immunotherapy Combo in Phase 2 Trial for Triple-negative Breast Cancer

ADC Therapeutics Halts ADCT-502 Development, Phase 1 Trial for HER2-positive Cancers

Breast Cancer Patients with Very Small Tumors May Skip Lymph Node Biopsies, Study Suggests

Pin It on Pinterest